A dispute over interpretation of the OCEAN trial data is at the heart of Oncopeptides' decision to test the waters of US FDA's new expedited withdrawal procedures. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
